Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Dutrebis, New HIV Drug, Approved by FDA, but Not Commercially Available

The new combination contains 150 mg of lamivudine (3TC, Epivir) and 300 mg of raltegravir (Isentress). Despite the FDA approval, the drug manufacturer, Merck Pharmaceuticals, announced that they would not be making Dutrebis commercially available in the U.S. at this time.

Published
11 February 2015
From
The Body Pro
HIV Organizations Urge Continuation of D:A:D Study

D:A:D follows 50,000 HIV-positive people, looking at drug safety and side effects over time. Results from D:A:D have changed HIV treatment guidelines, and how HIV-positive people are treated by their health care providers. We urge pharmaceutical companies to continue funding this vital study.

Published
11 February 2015
From
Treatment Action Group
A more personalised approach to hepatitis C treatment may improve adherence and completion rates

People receiving treatment for hepatitis C value clinicians who give information and clinical feedback that is personalised to their individual needs and lifestyle, and cite this as

Published
11 February 2015
By
Roger Pebody
CROI 2015 Preview: New Research on HIV, Hepatitis C and Ebola

It's the beginning of the year, which means another Conference on Retroviruses and Opportunistic Infections (CROI) is upon us. This year's CROI takes place in Seattle and should prove to be another exciting conference as new research is presented.

Published
11 February 2015
From
The Body Pro
US: A Call for Improved HIV-Related Scientific Literacy on the Front Lines

Poor scientific literacy among non-medical members of the HIV-related workforce must be addressed in order to better fight the epidemic. Many workers are unfamiliar with biomedical prevention of HIV—using antiretrovirals to reduce the risk of HIV transmission—and don’t know enough about how and when such an intervention should be used.

Published
10 February 2015
From
AIDSMeds
More African Americans still die of HIV than whites and Latinos combined, CDC says

More African Americans still die of HIV than whites and Latinos combined, the Centers for Disease Control and Prevention reported Thursday, but the black death rate is generally declining more quickly than it is for those other groups.

Published
09 February 2015
From
Washington Post
Aids denialism in London – It is really 2015?

The latest in a 30-year long effort to mislead the public was an event in London earlier this month. The Frontline Club – a charitable foundation supporting journalism around the world – chose to lend its venue and name to the promotion of a 16-year old, long discredited book by Joan Shelton questioning the proven link between HIV and AIDS.

Published
09 February 2015
From
Incidence 0
VOICE trial: Microbicide gel may have stopped two out of three HIV infections – in the women who used it

The final published paper on the VOICE trial in women in three African countries mainly reinforces what conference presentations have already shown: this ambitious trial failed to

Published
09 February 2015
By
Gus Cairns
CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy

CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that it had concluded its Phase 2b treatment substitution study and reported 39 patients out of 40 participating in the study passed 4 weeks of monotherapy with PRO 140.

Published
05 February 2015
From
CytoDyn press release
Researchers identify key mechanisms underlying HIV-associated cognitive disorders

New findings, published today by researchers at the University of California, San Diego School of Medicine, open the door to the development of new therapies to block or decrease cognitive decline due to HIV-associated neurocognitive disorders, estimated to affect 10 to 50 percent of aging HIV sufferers to some degree.

Published
04 February 2015
From
Medical Xpress

Filter by country